[go: up one dir, main page]

MX2018012285A - Metodos de tratamiento para enfermedades colestasicas y fibroticas. - Google Patents

Metodos de tratamiento para enfermedades colestasicas y fibroticas.

Info

Publication number
MX2018012285A
MX2018012285A MX2018012285A MX2018012285A MX2018012285A MX 2018012285 A MX2018012285 A MX 2018012285A MX 2018012285 A MX2018012285 A MX 2018012285A MX 2018012285 A MX2018012285 A MX 2018012285A MX 2018012285 A MX2018012285 A MX 2018012285A
Authority
MX
Mexico
Prior art keywords
colestic
fibrotic diseases
treatment methods
treatment
fibrotic
Prior art date
Application number
MX2018012285A
Other languages
English (en)
Other versions
MX386739B (es
Inventor
Walczak Robert
Foucart Corinne
Delataille Philippe
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2018012285A publication Critical patent/MX2018012285A/es
Publication of MX386739B publication Critical patent/MX386739B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fish Paste Products (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una combinación sinérgica de ingredientes activos para el uso en el tratamiento de enfermedades fibróticas.
MX2018012285A 2016-04-11 2017-03-13 Métodos de tratamiento para enfermedades colestásicas y fibróticas. MX386739B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305427 2016-04-11
PCT/EP2017/055880 WO2017178173A1 (en) 2016-04-11 2017-03-13 Methods of treatment for cholestatic and fibrotic diseases

Publications (2)

Publication Number Publication Date
MX2018012285A true MX2018012285A (es) 2019-02-07
MX386739B MX386739B (es) 2025-03-19

Family

ID=55755537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012285A MX386739B (es) 2016-04-11 2017-03-13 Métodos de tratamiento para enfermedades colestásicas y fibróticas.

Country Status (16)

Country Link
US (1) US20170290813A1 (es)
EP (1) EP3442518B1 (es)
JP (1) JP7134092B2 (es)
KR (1) KR102410951B1 (es)
CN (1) CN109152760B (es)
AU (1) AU2017249603B2 (es)
BR (1) BR112018069682A2 (es)
CA (1) CA3019205A1 (es)
CO (1) CO2018012180A2 (es)
EA (1) EA201892297A1 (es)
IL (1) IL262186B2 (es)
MX (1) MX386739B (es)
PH (1) PH12018502161A1 (es)
SG (1) SG11201808540SA (es)
WO (1) WO2017178173A1 (es)
ZA (1) ZA201807390B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368512B1 (en) * 2015-10-27 2023-12-06 Taipei Medical University Indoline derivatives for treatment and/or prevention of fibrosis diseases
HRP20201954T1 (hr) 2016-04-11 2021-02-05 Genfit Metode liječenja kolestatskih i fibrotičnih bolesti
CN110418641A (zh) * 2017-02-24 2019-11-05 基恩菲特公司 用于组合疗法的药物组合物
BR112019018162A2 (pt) 2017-03-13 2020-04-07 Genfit Composições farmacêuticas para terapia de combinação
CN109666739B (zh) * 2019-02-22 2019-07-30 无锡市妇幼保健院 一种与妊娠期肝内胆汁淤积症辅助诊断相关的血清/血浆LncRNA标志物组合及其应用
MA55592A (fr) 2019-04-10 2022-02-16 Genfit Polythérapie comprenant des composés de formule (i) et des agonistes du récepteur glp-1
WO2023286963A1 (ko) * 2021-07-15 2023-01-19 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 담관염(cholangitis) 또는 담관염에 의한 간 질환의 예방 또는 치료용 약학적 조성물
WO2023122869A1 (zh) * 2021-12-27 2023-07-06 浙江海正药业股份有限公司 瑞舒伐他汀钙在制备用于预防和治疗胆汁淤积及肝纤维化的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619500D0 (en) * 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
WO2008124384A2 (en) * 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
MX348282B (es) * 2009-02-13 2017-06-05 Romark Laboratories L C * Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
WO2013082469A2 (en) * 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
US9974767B2 (en) * 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies

Also Published As

Publication number Publication date
CN109152760A (zh) 2019-01-04
PH12018502161A1 (en) 2019-07-15
SG11201808540SA (en) 2018-10-30
IL262186B1 (en) 2023-06-01
KR20180129936A (ko) 2018-12-05
AU2017249603B2 (en) 2022-12-01
IL262186A (en) 2018-11-29
CA3019205A1 (en) 2017-10-19
EP3442518A1 (en) 2019-02-20
JP7134092B2 (ja) 2022-09-09
IL262186B2 (en) 2023-10-01
WO2017178173A1 (en) 2017-10-19
AU2017249603A1 (en) 2018-10-18
MX386739B (es) 2025-03-19
CN109152760B (zh) 2022-09-23
EP3442518B1 (en) 2024-01-17
BR112018069682A2 (pt) 2019-01-29
JP2019513760A (ja) 2019-05-30
EA201892297A1 (ru) 2019-07-31
KR102410951B1 (ko) 2022-06-20
CO2018012180A2 (es) 2019-08-20
US20170290813A1 (en) 2017-10-12
ZA201807390B (en) 2019-08-28

Similar Documents

Publication Publication Date Title
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX378273B (es) Compuestos activos hacia bromodominios.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016002971A1 (es) Combinación.
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
ZA201906100B (en) Combination of a ppar agonist with a fxr agonist
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX383944B (es) Composiciones para el cuidado personal.
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX2016014166A (es) Compuestos de triaminopirimidina utiles para evitar o tratar la malaria.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas